3 terminated, 2 completed, 1 suspended. 3 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Suspended 1, Terminated 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Syros Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia SY-2101, Arsenic Trioxide - Acute Promyelocytic Leukemia | Phase 1 | Suspended | Syros Pharmaceuticals | 16 | 2021-09-17 | 2024-01-23 |
| Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Tamibarotene, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 2 | Terminated | Syros Pharmaceuticals | 66 | 2021-08-26 | 2025-02-24 |
| Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome Tamibarotene, Placebo, Azacitidine - Myelodysplastic Syndromes | Phase 3 | Terminated | Syros Pharmaceuticals | 246 | 2021-02-08 | 2025-04-10 |
| A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors SY-5609, Fulvestrant, Gemcitabine - Advanced Solid Tumor, Breast Cancer | Phase 1 | Completed | Syros Pharmaceuticals | 105 | 2020-01-23 | 2023-10-27 |
| A Study of SY-1365 in Adult Patients With Advanced Solid Tumors SY-1365 (Part 1), Carboplatin, Fulvestrant - Advanced Solid Tumors, Ovarian Cancer | Phase 1 | Terminated | Syros Pharmaceuticals | 107 | 2017-05-12 | 2021-03-09 |
| A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome Tamibarotene, Azacitidine, Daratumumab - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Completed | Syros Pharmaceuticals | 155 | 2016-09-20 | 2024-12-13 |
Breast Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (2) · Leukemia, Promyelocytic, Acute (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Small Cell Lung Carcinoma (1)
Azacitidine (3) · tamibarotene (3) · Fulvestrant (2) · 130-nm albumin-bound paclitaxel (1) · Arsenic Trioxide (1) · Carboplatin (1) · Gemcitabine (1) · SY-5609 (1) · cyclo-tetrakis(bis(1-phenyl-3-methyl-4-benzoylpyrazolon-5-ato)mu-oxotitanium(IV)) (1) · daratumumab (1) · mevociclib (1) · venetoclax (1)
United States (6) · France (4) · Canada (2) · Austria (1) · Belgium (1) · Czechia (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Poland (1) · Spain (1) · United Kingdom (1)
Kate Madigan, MD (1)
PMID 32385714, PMID 34726887, PMID 36477975, PMID 38065202, PMID 40020161, PMID 40334070, PMID 42761251
2017 (1)